文献速递认知障碍与痴呆

血浆p-tau217与[18F]FDG-PET在早发性或非典型痴呆中识别阿尔茨海默病的比较

Comparison of Plasma p-tau217 and [18F]FDG-PET for Identifying Alzheimer Disease in People With Early-Onset or Atypical Dementia.
PubMed 文献 · Neurology · 2024-12-23

本研究回顾性分析81例早发性和/或非典型痴呆患者,比较血浆p-tau217免疫测定与[18F]FDG-PET视觉评估对阿尔茨海默病生物标志物谱的诊断性能。血浆p-tau217的敏感性(97%)高于[18F]FDG-PET(73%),总体准确率也更高(AUC 84% vs 72%),两者特异性相似(均为70%)。

要点

  • 血浆p-tau217对AD的敏感性为97%,高于[18F]FDG-PET的73%(p=0.01)。
  • 两者特异性均为70%,无显著差异。
  • 血浆p-tau217总体准确率AUC 84%,高于[18F]FDG-PET的72%(p=0.02)。

核心结论

  • 在专科记忆门诊评估的早发性和/或非典型痴呆患者中,血浆p-tau217对AD具有强判别准确性,未来需在二级医疗环境中重复这些发现。

研究设计与样本

  • 回顾性分析在三级记忆门诊评估的早发性和/或非典型痴呆个体,共纳入81例,平均年龄65岁,女性48/81(59%)。
  • 所有参与者均接受脑脊液生物标志物(Aβ42、p-tau181、总tau)、[18F]FDG-PET、淀粉样蛋白-PET和血浆p-tau217定量检测。
  • [18F]FDG-PET图像由2名核医学专家视觉判读是否与AD兼容。

主要发现

  • 血浆p-tau217对AD的敏感性为97%(CI: 0.85-0.99),高于[18F]FDG-PET的73%(CI: 0.57-0.85)(p=0.01)。
  • 两者特异性均为70%(CI: 0.56-0.81)。
  • 血浆p-tau217总体准确率AUC为84%(CI: 0.75-0.93),高于[18F]FDG-PET的72%(CI: 0.60-0.83)(p=0.02)。
  • 以淀粉样蛋白-PET为参考标准时观察到相同模式的结果。

局限性

  • 未来工作应在二级医疗环境中重复这些发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: To compare the diagnostic performance of an immunoassay for plasma concentrations of phosphorylated tau (p-tau) 217 with visual assessments of fluorine-18 fluorodeoxyglucose [18F]FDG-PET in individuals who meet appropriate use criteria for Alzheimer dementia (AD) biomarker assessments. METHODS: We performed a retrospective analysis of individuals with early-onset (age <65 years at onset) and/or atypical dementia (features other than memory at onset), who were evaluated at a tertiary care memory clinic. All participants underwent measurements of CSF biomarkers (Aβ42, p-tau181, and total tau levels), as well as [18F]FDG-PET scans, amyloid-PET scans, and plasma p-tau217 quantifications. To determine whether the [18F]FDG-PET images were compatible with AD, images were visually rated by 2 nuclear medicine experts. Using a contingency analysis, we evaluated the accuracy of [18F]FDG-PET scan interpretation and plasma p-tau217 for an AD biomarker profile in CSF and for amyloid-PET positivity. RESULTS: A total of 81 individuals with early onset and/or atypical dementia were included in this study (mean age = 65 years; 48/81 female (59%). Both [18F]FDG-PET and plasma p-tau217 showed high levels of agreement with reference standard AD biomarkers ([18F]FDG-PET area under the curve [AUC]: 71%; plasma p-tau217 AUC: 81%). Although both biomarkers had similar specificity for AD [18F]FDG-PET: 70%, CI: 0.56-0.81; plasma p-tau217: 70%, CI: 0.56-0.81), plasma p-tau217 had higher sensitivity for AD (plasma p-tau217: 97%, CI: 0.85-0.99 vs [18F]FDG-PET: 73%, CI: 0.57-0.85) (p = 0.01). Overall accuracy was also higher for plasma p-tau217 (AUC = 84%, CI: 0.75-0.93 vs 72%, CI: 0.60-0.83 of [18F]FDG-PET) (p = 0.02). The same pattern of results was observed when using amyloid-PET as the reference standard. DISCUSSION: Our study provides evidence that plasma p-tau217 has strong discriminative accuracy for AD among patients with early-onset and/or atypical dementia assessed in specialized settings. Future work should replicate these findings in secondary care settings.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Quispialaya KM, Therriault J, Aliaga A, et al. Comparison of Plasma p-tau217 and [18F]FDG-PET for Identifying Alzheimer Disease in People With Early-Onset or Atypical Dementia. Neurology. 2024. PMID: 39715476. doi:10.1212/WNL.0000000000210211

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。